Bionano Genomics | ARS: Annual Report to Security Holders
Bionano Genomics | 4: Statement of changes in beneficial ownership of securities-Officer Chaubey Alka
Bionano Genomics | 4: Statement of changes in beneficial ownership of securities-Officer Dixon Jonathan V.
Bionano Genomics | 4: Statement of changes in beneficial ownership of securities-Officer Holmlin R. Erik
Bionano Genomics | 4: Statement of changes in beneficial ownership of securities-Officer OLDAKOWSKI MARK
Bionano Genomics | 10-K: Annual report
Bionano Genomics | 8-K: Bionano Reports Fourth Quarter and Full-Year 2023 Results and Provides Revenue Outlook for 2024
Bionano Genomics | 8-K: Bionano Announces Amendment to Debt Financing Arrangement to Extend Cash Runway
Bionano Genomics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-The Vanguard Group(4.88%)
Bionano Genomics | 8-K: Bionano Reports Preliminary Fourth Quarter and Full-Year 2023 Results
Bionano Genomics | 8-K: Current report
Bionano Genomics | 424B3: Prospectus
Bionano Genomics: Q3 2023 Earnings Report
Bionano Genomics | 8-K: Bionano Reports Third Quarter 2023 Results and Highlights Recent Business Progress
Bionano Genomics | EFFECT: Others
Bionano Genomics | CORRESP: CORRESP
Bionano Genomics | UPLOAD: Others
Bionano Genomics | D: Filing D
Bionano Genomics | S-3: Registration statement for specified transactions by certain issuers
Bionano Genomics | 8-K: Bionano Prices $80.0 Million Financing in Convertible Notes and Warrants, Announces Preliminary Q3 2023 Results, and Implements Streamlined Operational Plan
No Data